Defective Central Memory CD8+ T Cell Differentiation in the Absence of Eomesodermin.

Arnob Banerjee(Johnson & Johnson (United States)), Steven L. Reiner(Columbia University Irving Medical Center), Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center), Scott M. Gordon(Cancer Research Institute of the Slovak Academy of Sciences), E. John Wherry(Parker Institute for Cancer Immunotherapy)
Blood
November 20, 2009
10.1182/blood.v114.22.2662.2662
Cited by 0

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
|Science|2021|932
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873